Chiron Real Estate Inc

Análisis de la acción Chiron Real Estate Inc (XRN)

$36.820

-0.070 (-0.19%)Al cierre

Loading chart…
High
37.290
Open
37.060
VWAP
36.90
Vol
70.41K
Mkt Cap
Low
36.600
Amount
2.60M
EV/EBITDA, TTM
11.82

Chiron Real Estate Inc., formerly Global Medical REIT Inc., is an internally managed real estate investment trust (REIT). The Company acquires healthcare facilities leased to physician groups and regional and national healthcare systems. The Company conducts its business through its limited partnership subsidiary, Chiron Real Estate LP (operating partnership). It owns 92.0% of the outstanding common operating partnership units (OP Units) of its operating partnership, with an aggregate of 8.0% of the operating partnership owned by holders of long-term incentive plan units (LTIP Units) and third-party limited partners who contributed properties or services to the Operating Partnership in exchange for OP Units. Its portfolio includes medical office buildings (MOBs), inpatient rehab. facility (IRF), surgical hospitals and others. Its portfolio is located in various areas, including Texas, Florida, Ohio, Arizona, Pennsylvania, Illinois, and Others.

AI analysis of Chiron Real Estate Inc (XRN)

hold

Chiron Real Estate Inc is currently a hold. The stock's current price is $36.82, which is below the analyst price target range of $40 to $43, indicating potential upside. However, the RSI is at 47.423, suggesting that the stock is neither overbought nor oversold, and the forward P/E ratio is 44.44, indicating high valuation concerns. The recent Q2 earnings showed a strong FFO of $0.88, beating expectations, but the company's transition strategy may dilute earnings in the short term. The main risk is the high forward P/E ratio, which may lead to volatility if earnings do not meet expectations.

Métricas de valoración

The current forward P/E ratio for Chiron Real Estate Inc (XRN) is 44.44, compared to its 5-year average forward P/E of 189.32.

Forward P/E

Strongly Undervalued
5Y Average P/E
189.32
Current P/E
44.44
Sobrevalorada
249.20
Infravalorada
129.44

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
12.67
Current EV/EBITDA
11.82
Sobrevalorada
14.76
Infravalorada
10.57

Forward P/S

Fair
5Y Average P/S
3.85
Current P/S
3.25
Sobrevalorada
5.02
Infravalorada
2.67

Whales holding XRN

H

Heartland Advisors, Inc.

+ HoldingXRN

+5.63%

3M Return

Cronología de eventos

2026-08-05 (ET)

17:30:00

Chiron CEO Highlights Progress in Capital Allocation and Investments

2026-08-03 (ET)

17:00:00

Chiron Appoints Matthew Whitlock as Chief Investment Officer

2026-07-17 (ET)

17:00:00

Chiron Real Estate Appoints New Executives

2026-07-14 (ET)

16:30:00

Chiron Real Estate Appoints New Executive Team

2026-06-30 (ET)

09:30:00

Chiron Real Estate Sells Seven Rehab Facilities for $217M

Noticias

XRN FAQ — answered by Alphio AI

Chiron Real Estate Inc., formerly Global Medical REIT Inc., is an internally managed real estate investment trust (REIT). The Company acquires healthcare facilities leased to physician groups and regional and national healthcare systems. The Company conducts its business through its limited partnership subsidiary, Chiron Real Estate LP (operating partnership). It owns 92.0% of the outstanding common operating partnership units (OP Units) of its operating partnership, with an aggregate of 8.0% of the operating partnership owned by holders of long-term incentive plan units (LTIP Units) and third-party limited partners who contributed properties or services to the Operating Partnership in exchange for OP Units. Its portfolio includes medical office buildings (MOBs), inpatient rehab. facility (IRF), surgical hospitals and others. Its portfolio is located in various areas, including Texas, Florida, Ohio, Arizona, Pennsylvania, Illinois, and Others. It operates in the Real Estate sector.

Chiron Real Estate Inc is currently a hold. The stock's current price is $36.82, which is below the analyst price target range of $40 to $43, indicating potential upside. However, the RSI is at 47.423, suggesting that the stock is neither overbought nor oversold, and the forward P/E ratio is 44.44, indicating high valuation concerns. The recent Q2 earnings showed a strong FFO of $0.88, beating expectations, but the company's transition strategy may dilute earnings in the short term. The main risk is the high forward P/E ratio, which may lead to volatility if earnings do not meet expectations.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis